← Leaderboards
Tina Garyantes
Linnaeus Therapeutics, Llc
$6,999,960
Attributed
$6,999,960
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,999,960 · 2
By mechanism
R44$6,999,960 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Receptor”
- Xinhua Li · Nano Terra, Inc.$32,520,955
- Jeffrey Reich · Sparian Biosciences, Inc.$28,575,028
- Jay Evans · University Of Montana$23,751,494
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$22,797,910
- Julie Ake · National Institute Of Allergy And Infectious Diseases$22,000,000
- Andrew S Huhn · Johns Hopkins University$17,444,676
Research focus
ReceptorReceptor ExpressionPharmaceutical PreparationsPre-ClinicalOralReceptor ActivationMalignant NeoplasmsPennsylvaniaGper GenePhase I Clinical TrialsCombinatorialMelanomaNeoplastic CellNew Therapeutic TargetCancer TypeDesignCapital FinancingDoseFormulationFutureImmunotherapyImproved OutcomeAgonistResponse
Grant awards (5)
Development of LNS8801 for cutaneous melanoma patients who cannot tolerate immunotherapy$999,960
R44 · FY2025 · CA · contact PI
Development of GPER Agonists as Therapeuticsfor Cutaneous and Uveal Melanoma$2,000,000
R44 · FY2023 · CA · contact PI
Development of GPER Agonists as Therapeuticsfor Cutaneous and Uveal Melanoma$2,000,000
R44 · FY2022 · CA · contact PI
Development of GPER Agonists as Cancer Therapeutics$1,000,000
R44 · FY2020 · CA · contact PI
Development of GPER Agonists as Cancer Therapeutics$1,000,000
R44 · FY2019 · CA · contact PI